Skip to main content

Advertisement

Table 1 Cell viability of hypoxic human colorectal carcinoma cell lines

From: Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells

Cell line Mutations ABT-737 AZD8055 combo-Rx p-value
HCT-116 KRAS, PIK3CA 89.4 ± 19.1 73.0 ± 10.9 46.1 ± 13.7 0.0016
HCT-15 KRAS, PIK3CA 92.7 ± 2.31 89.7 ± 3.79 68.0 ± 10.4 0.028
SW620 KRAS 80.6 ± 8.91 77.8 ± 13.4 28.0 ± 3.46 <0.001
SW480 KRAS 99.0 ± 3.46 71.0 ± 12.1 41.7 ± 8.39 0.026
HCC2998 KRAS 85.3 ± 6.41 96.0 ± 14.2 37.0 ± 8.37 <0.001
LoVo KRAS 101 ± 10.3 64.0 ± 7.21 58.7 ± 8.50 0.45
RKO BRAF, PIK3CA 95.0 ± 12.8 65.3 ± 3.79 68.3 ± 5.03 0.46
KM20L2 BRAF 100 ± 4.62 90.9 ± 7.38 80.7 ± 6.63 0.019
WiDr BRAF 98.3 ± 1.71 99.0 ± 3.46 68.7 ± 21.6 0.074
HT-29 BRAF 97.3 ± 7.48 86.0 ± 8.54 79.0 ± 11.4 0.44
CO-115 BRAF 86.3 ± 2.89 69.7 ± 2.52 58.7 ± 2.52 0.0059
Caco-2 wild-type 90.4 ± 17.0 60.1 ± 15.3 42.3 ± 17.9 0.068
Colo320DM wild-type 102 ± 6.73 54.9 ± 4.56 54.9 ± 5.46 1.0
SNU-C1 wild-type 83.0 ± 11.4 107 ± 20.0 68.0 ± 15.9 0.023
  1. From between three and seven independent experiments, each at least with triplicate setups, mean ± SD cell viability values were calculated in percentage of values from the corresponding controls (vehicle-treated cells). Treatments (24-h incubations): ABT-737 (inhibitor of anti-apoptotic Bcl-2 family proteins; 10 μM), AZD8055 (mTOR inhibitor; 10 μM), combo-Rx (10 μM of both compounds in combination). Difference in values from cells given AZD8055 or combo-Rx was compared by two-tailed Student’s t-test. Mutation status is indicated for each cell line